



May 16, 2022

RE: GSK Orphan Drug Contract – NUCALA and ZEJULA

To PHS Covered Entity:

As you are aware, certain 340B covered entities are subject to the orphan drug exclusion under the 340B statute at 42 U.S.C. § 256b(e). Under this provision, drugs with an orphan drug designation are excluded from the definition of "covered outpatient drug"; thus manufacturers are not required to extend 340B pricing on orphan drugs to entities subject to the exclusion. Any such pricing is voluntary, at the manufacturer's discretion.

This letter is to inform you that, consistent with 340B statute, effective July 1, 2022, GSK will no longer offer voluntary 340B pricing on orphan drugs to entities subject to the 340B orphan drug exclusion.

Current voluntary pricing will continue through June 30, 2022.

This change will not impact 340B grantees or covered entities not subject to the orphan drug exclusion. If you have questions about GSK 340B pricing, please contact GSK at [US.340B@gsk.com](mailto:US.340B@gsk.com)

Regards,

GSK 340B Contracting Team

<b>Product Description</b>	<b>NDC</b>
NUCALA (MEPOLZUMAB) INJ 100MG 1 VIAL/CARTON	00173-0881-01
ZEJULA CAPSULE 100MG 1X30	69656-0103-30